Skip to content
DataLookout
Menu

NCT07780669

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 7 → 11 locations
  2. Minor Study sites: 7 to 9
  3. Notable Eligibility criteria expanded, about 17 words
    • Trial sites expanded: 2 → 7 locations
    • Secondary endpoints: details revised at 2 of 5 entries
  4. Notable Recruitment opened
    • Study sites: 0 to 2
    • Start date changed from estimate of Aug 31, 2026 to Aug 27, 2026
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Annualized rate of moderate or severe COPD Exacerbations
Timeframe: Up to Week 78

Secondary (5)

Change from Baseline in St. George's respiratory questionnaire (SGRQ) total score
Change from Baseline in pre-Bronchodilator Forced expiratory volume in 1 second (FEV1)
Annualized rate of COPD exacerbations requiring emergency department (ED) visit or hospitalization
Annualized rate of moderate/severe COPD exacerbations among participants with elevated screening blood eosinophil counts (BEC)
Time to first moderate or severe COPD exacerbation

Arms and interventions

Participants receiving GSK5784283 plus standard of careExperimental
Participants receiving matching placebo plus standard of carePlacebo comparator

Drugs: GSK5784283, Placebo, Standard of care

Sites

11 sites in 2 countries

United States 7, Japan 4